دورية أكاديمية
Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production
| العنوان: | Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production |
|---|---|
| المؤلفون: | Carlos Ramos-Acosta, Laura Huerta-Pantoja, Milton Eduardo Salazar-Hidalgo, Elsa Mayol, Selene Jiménez-Vega, Pablo García-Peña, Jenifeer Jordi-Cruz, Cristina Baquero, Almudena Porras, Belén Íñigo-Rodríguez, Celina M. Benavente, Andrea R. López-Pastor, Irene Gómez-Delgado, Elena Urcelay, Francisco Javier Candel, Eduardo Anguita |
| المصدر: | International Journal of Molecular Sciences, Vol 25, Iss 9, p 4887 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Biology (General) LCC:Chemistry |
| مصطلحات موضوعية: | multiple myeloma, tigecycline, bortezomib, ROS, cell cycle, antagonism, Biology (General), QH301-705.5, Chemistry, QD1-999 |
| الوصف: | Multiple myeloma is an incurable plasma cell malignancy. Most patients end up relapsing and developing resistance to antineoplastic drugs, like bortezomib. Antibiotic tigecycline has activity against myeloma. This study analyzed tigecycline and bortezomib combination on cell lines and plasma cells from myeloma patients. Apoptosis, autophagic vesicles, mitochondrial mass, mitochondrial superoxide, cell cycle, and hydrogen peroxide were studied by flow cytometry. In addition, mitochondrial antioxidants and electron transport chain complexes were quantified by reverse transcription real-time PCR (RT-qPCR) or western blot. Cell metabolism and mitochondrial activity were characterized by Seahorse and RT-qPCR. We found that the addition of tigecycline to bortezomib reduces apoptosis in proportion to tigecycline concentration. Supporting this, the combination of both drugs counteracts bortezomib in vitro individual effects on the cell cycle, reduces autophagy and mitophagy markers, and reverts bortezomib-induced increase in mitochondrial superoxide. Changes in mitochondrial homeostasis and MYC upregulation may account for some of these findings. These data not only advise to avoid considering tigecycline and bortezomib combination for treating myeloma, but caution on the potential adverse impact of treating infections with this antibiotic in myeloma patients under bortezomib treatment. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1422-0067 1661-6596 |
| Relation: | https://www.mdpi.com/1422-0067/25/9/4887; https://doaj.org/toc/1661-6596; https://doaj.org/toc/1422-0067 |
| DOI: | 10.3390/ijms25094887 |
| URL الوصول: | https://doaj.org/article/4049cf76f6d34ed197c0d2a01eb079da |
| رقم الأكسشن: | edsdoj.4049cf76f6d34ed197c0d2a01eb079da |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14220067 16616596 |
|---|---|
| DOI: | 10.3390/ijms25094887 |